MedPath

The effect of a hemoperfusio

Not Applicable
Conditions
Symptoms, signs and abnormal clinical and laboratory findings, NEC
Registration Number
KCT0006727
Lead Sponsor
Asan Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

The study includes septic shock patients aged 19 or older who meet all of the following conditions:
(1) Adults 19 years of age or older
(2) Community aquired infection: Infection occurring within 48 hours of hospitalization
(3) Sepsis (Definition of SEPSIS-3): Infection + 2 or more points of SOFA compared to base
(4) Septic shock (Definition of SEPSIS-3): use of vasopressor + Lactic acid > 2 mmol/L
(5) Use of vasopressor: 0.2 mcg/kg/min of norepinephrine for more than one hour.

Exclusion Criteria

It is excluded from the study if one or more of the following conditions apply:
(1) Under 19 years of age or over 80 years of age;
(2) Patients who have elapsed more than 24 hours after septic shock occurs
(3) Severe neutrophil count reduction: ANC < 500/microL
(4) Patients who have received organ transplants within 12 months
(5) Blood cancer patients
(6) Solid cancer patients who have undergone chemotherapy within three months
(7) Patients under dialysis treatment for chronic renal failure
(8) Patients with a screening SOFA score of 12 or higher
(9) Patients with adverse reactions to heparin (e.g. HIT)
(10) Patients who have applied in ECMO(Extracorporeal Membrane Oxygenation) treatment
(11) Pregnant women and lactating women
(12) Patients participating in other clinical trials
(However, not excluded from studies without arbitration, e.g. cohort observation studies)
(13) Patients with ECOG of 3 or more points
(14) Patients who are expected to die within six months due to a companion disease
(15) Patients who have performed CPR with Cardiac arrest
(16) Do-not-resuscitation (DNR) status patient

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in the use of vasopressor(cumulative vasopressor index, CVI) after random assignments
Secondary Outcome Measures
NameTimeMethod
Changes in Sequential Organ Failure Assessment (SOFA) scores after random assignments;Changes in Disseminated Intravascular Coagulation (DIC) scores after random assignments;Changes in IL-1ß, IL-6, IL-8, IL-10, TNF-a after random assignments;Mortality;Hospital mortality rates;Hospital days;ICU days and ICU-free day;Ventilator-free days and vasopressor-free days
© Copyright 2025. All Rights Reserved by MedPath